MINNEAPOLIS, Nov. 16, 2022 (GLOBE NEWSWIRE) -- CVRx, Inc. (“CVRx”), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, today announced that the management team will participate in the Piper Sandler 34th Annual Healthcare Conference on Wednesday, November 30, 2022. The Company is scheduled to present at the conference at 8:00 am Eastern Time the same day via webcast.

The new Barostim NEO2 Implantable Pulse Generator (IPG) launches in the U.S., improving the patient experience while on therapy and simplifying the implant procedure for physicians MINNEAPOLIS, Nov. 03, 2022 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) (“CVRx”), developer of the world’s first FDA-approved neuromodulation device to treat the symptoms of heart failure, has launched its new

CVRx Earnings, Revenue Beat in Q3

CVRx, Inc. (NASDAQ:NASDAQ:CVRX) Q3 2022 Earnings Conference Call November 01, 2022, 05:30 PM ET Company Participants Mike Vallie - Westwicke, ICR Company Nadim Yared - President and CEO…

Third quarter 2022 revenue of $6.2 million, an 82% increase over prior year Third quarter 2022 revenue of $6.2 million, an 82% increase over prior year

CVRx (NASDAQ: CVRX ) is set to give its latest quarterly earnings report on Tuesday, 2022-11-01. Here''s what investors need to know before the announcement. Analysts estimate that CVRx will report an earnings per share (EPS) of $-0.56. CVRx bulls will hope to hear the company to announce they''ve not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the … Full story available on Benzinga.com

MINNEAPOLIS, Oct. 18, 2022 (GLOBE NEWSWIRE) -- CVRx, Inc. (“CVRx”), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, today announced that it plans to release third quarter 2022 financial and operating results after market close on Tuesday, November 1st, 2022. The Company will host a conference call to review its results at 5:30 p.m. Eastern Time the same day. The conference call will be broadcast live in listen-only mode via webcast at https://edge.media-server.com/mmc/p/8kfcmjvb . To listen to the conference call on your telephone, participants may register for the call here . While it is not required, it is recommended you join 10 minutes prior to the event start. About CVRx, Inc. CVRx is focused on the development and commercialization of Barostim™, the first medical technology approved by FDA that uses neuromodulation to improve the symptoms of patients with heart failure.